Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Tests, Methods, Platforms, Applications, 26 Countries’ Analysis, Patent Landscape, and Competitive Landscape - Analysis and Forecast, 2018-2028
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
The life science industry is focused on the development of advanced NIPT tests using genome sequencing technologies for the early detection of genetic disorders. The increasing prevalence of genetic disorders and development of the healthcare infrastructure are promoting the adoption of the NIPT for better diagnosis and improved prenatal care.
Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered as a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. Moreover, advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.
The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The market has been segmented into ‘tests,’ ‘methods,’ ‘platforms,’ ‘applications,’ and ‘regions.’ The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
This research report aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global NIPT market. Moreover, the study includes detailed product mapping with further sub-segmentation in various countries, and in each sub-segment, the key market trends, list of the key companies, and the key strategies and developments have also been discussed.
The answers to the following key questions can be derived from this report:
The life science industry is focused on the development of advanced NIPT tests using genome sequencing technologies for the early detection of genetic disorders. The increasing prevalence of genetic disorders and development of the healthcare infrastructure are promoting the adoption of the NIPT for better diagnosis and improved prenatal care.
Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered as a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. Moreover, advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.
The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The market has been segmented into ‘tests,’ ‘methods,’ ‘platforms,’ ‘applications,’ and ‘regions.’ The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
This research report aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global NIPT market. Moreover, the study includes detailed product mapping with further sub-segmentation in various countries, and in each sub-segment, the key market trends, list of the key companies, and the key strategies and developments have also been discussed.
The answers to the following key questions can be derived from this report:
- How did the NIPT market evolve, and what is its scope in the future?
- What are the major market drivers, challenges, and opportunities in the global NIPT market?
- What are the key developmental strategies that are implemented by the key players to sustain in this market?
- How the influencing factors will affect the industry attractiveness?
- How NIPT is utilized for the detection of chromosomal abnormalities?
- How investments by public and private companies and government organizations will affect the global NIPT market?
- What was the market size of the leading segments and sub-segments of the global NIPT market in 2017?
- How will the industry evolve during the forecast period 2018-2028?
- What will be the growth rate of the NIPT during the forecast period?
- How will each segment of the global NIPT market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
- Which test segment, and application segment is expected to register the highest CAGR for the NIPT market?
- What is the market size of NIPT in different countries of the world?
- Which geographical region will contribute to the highest sales of NIPT?
- Who are the key players in the NIPT market, and what are their contributions?
EXECUTIVE SUMMARY
1 MARKET OVERVIEW
1.1 Introduction
1.2 NIPT Approach
1.3 Different Methods of NIPT
1.4 Benefits and Risks Associated with NIPT
1.5 Technological Advancements
1.6 World Economic Outlook of Prenatal Testing Market, 2017
1.7 Global NIPT Market Scenario
1.8 Assumptions and Limitations for Market Size Calculations
2 MARKET DYNAMICS
2.1 Overview
2.2 Impact Analysis
2.3 Market Drivers
2.4 Market Restraints
2.5 Market Opportunities
3 COMPETITIVE LANDSCAPE
3.1 Introduction
3.2 Key Developments and Strategies
3.2.1 Product Launches and Enhancements
3.2.2 Joint Ventures, Partnerships, and Collaborations
3.2.3 Mergers and Acquisitions
3.2.4 Business Expansions, Awards, Recognitions, Certifications, and Others
3.3 Market Share Analysis
3.4 Growth Share Matrix (by Test), 2017
3.5 Growth Share Matrix (by Region), 2017
3.6 Key Stakeholders of NIPT Market
3.7 Industry Attractiveness
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Threat of New Entrants
3.7.4 Threat of Substitute Products
3.7.5 Intensity of Competitive Rivalry
4 INDUSTRY INSIGHTS
4.1 Introduction
4.2 Patent Analysis
4.3 Clinical Laboratory Improvement Amendments (CLIA) Program
4.4 List of Regulatory Bodies
5 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY TEST)
5.1 Overview
5.2 Verifi
5.3 MaterniT21 PLUS and MaterniT GENOME
5.4 PrenaTest, GeneSafe, and PrenatalSAFE
5.5 Panorama
5.6 QNatal Advanced
5.7 Harmony
5.8 IONA
5.9 NIFTY
5.10 Bambni
5.11 Others
6 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY METHOD)
6.1 Overview
6.2 cf-DNA
6.3 FCMB
7 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY PLATFORM)
7.1 Overview
7.2 NGS
7.3 MPSS
7.4 Others
8 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY APPLICATION)
8.1 Overview
8.2 Trisomy Detection
8.3 Microdeletion Detection
8.4 Others
9 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY REGION)
9.1 Overview
9.2 Global Insights
9.3 North America
9.3.1 North America Market Dynamics
9.3.2 North America Market (by Country)
9.3.2.1 The U.S.
9.3.2.2 Canada
9.4 Europe
9.4.1 Europe Market Dynamics
9.4.2 Europe Market (by Country)
9.4.2.1 The U.K.
9.4.2.2 Germany
9.4.2.3 France
9.4.2.4 Italy
9.4.2.5 Spain
9.4.2.6 The Netherlands
9.4.2.7 Belgium
9.4.2.8 Switzerland
9.4.2.9 Sweden
9.4.2.10 Denmark
9.4.2.11 Poland
9.4.2.12 Russia
9.4.2.13 Rest-of-Europe
9.5 Asia-Pacific
9.5.1 Asia-Pacific Market Dynamics
9.5.2 Asia-Pacific (by Country)
9.5.2.1 China
9.5.2.2 Japan
9.5.2.3 Australia
9.5.2.4 India
9.5.2.5 Singapore
9.5.2.6 Hong Kong
9.5.2.7 Malaysia
9.5.2.8 Indonesia
9.5.2.9 Vietnam
9.5.2.10 South Korea
9.5.2.11 Philippines
9.5.2.12 Thailand
9.5.2.13 Rest-of-Asia-Pacific
9.6 Rest-of-the-World
10 COMPANY PROFILES
10.1 Overview
10.2 Agilent Technologies, Inc.
10.2.1 Overview
10.2.2 Corporate Summary
10.2.3 Product Offerings for Global NIPT Market
10.2.4 Financials
10.2.4.1 Financial Summary
10.2.5 SWOT Analysis
10.3 Annoroad Gene Technology
10.3.1 Overview
10.3.2 Corporate Summary
10.3.3 Product Offerings for Global NIPT Market
10.3.4 SWOT Analysis
10.4 Berry Genomics Co., Ltd.
10.4.1 Overview
10.4.2 Corporate Summary
10.4.3 Product Offerings for Global NIPT Market
10.4.4 SWOT Analysis
10.5 BGI Diagnosis
10.5.1 Overview
10.5.2 Corporate Summary
10.5.3 Product Offerings for Global NIPT Market
10.5.4 SWOT Analysis
10.6 Centogene AG
10.6.1 Overview
10.6.2 Corporate Summary
10.6.3 Product Offerings for Global NIPT Market
10.6.4 SWOT Analysis
10.7 Counsyl, Inc. (Subsidiary of Myriad Genetics, Inc.)
10.7.1 Overview
10.8 Myriad Genetics, Inc.
10.8.1 Overview
10.8.2 Corporate Summary
10.8.3 Product Offerings for Global NIPT Market
10.8.4 Financials
10.8.4.1 Financial Summary
10.8.5 SWOT Analysis
10.9 LifeCodexx AG (Subsidiary of Eurofins Scientific)
10.9.1 Overview
10.10 EUROFINS Genoma Group (Subsidiary of Eurofins Scientific)
10.10.1 Overview
10.11 Eurofins Scientific
10.11.1 Overview
10.11.2 Corporate Summary
10.11.3 Product Offerings for Global NIPT Market
10.11.4 Financials
10.11.4.1 Financial Summary
10.11.5 SWOT Analysis
10.12 F. Hoffmann-La Roche AG
10.12.1 Overview
10.12.2 Corporate Summary
10.12.3 Product Offerings for Global NIPT Market
10.12.4 Financials
10.12.4.1 Financial Summary
10.12.5 SWOT Analysis
10.13 Illumina, Inc.
10.13.1 Overview
10.13.2 Corporate Summary
10.13.3 Product Offerings for Global NIPT Market
10.13.4 Financials
10.13.4.1 Financial Summary
10.13.5 SWOT Analysis
10.14 Natera, Inc.
10.14.1 Overview
10.14.2 Corporate Summary
10.14.3 Product Offerings for Global NIPT Market
10.14.4 Financials
10.14.4.1 Financial Summary
10.14.5 SWOT Analysis
10.15 Next Biosciences
10.15.1 Overview
10.15.2 Corporate Summary
10.15.3 Product Offerings for Global NIPT Market
10.15.4 SWOT Analysis
10.16 NIPD Genetics
10.16.1 Overview
10.16.2 Corporate Summary
10.16.3 Product Offerings for Global NIPT Market
10.16.4 SWOT Analysis
10.17 PerkinElmer, Inc.
10.17.1 Overview
10.17.2 Corporate Summary
10.17.3 Product Offerings for Global NIPT Market
10.17.4 Financials
10.17.4.1 Financial Summary
10.17.5 SWOT Analysis
10.18 Premaitha Health Plc
10.18.1 Overview
10.18.2 Corporate Summary
10.18.3 Product Offerings for Global NIPT Market
10.18.4 Financials
10.18.4.1 Financial Summary
10.18.5 SWOT Analysis
10.19 Quest Diagnostics Incorporated
10.19.1 Overview
10.19.2 Corporate Summary
10.19.3 Product Offerings for Global NIPT Market
10.19.4 Financials
10.19.4.1 Financial Summary
10.19.5 SWOT Analysis
10.20 Sequenom, Inc. (Subsidiary of Laboratory Corporation of America Holdings)
10.20.1 Overview
10.21 Laboratory Corporation of America Holdings
10.21.1 Overview
10.21.2 Corporate Summary
10.21.3 Product Offerings for Global NIPT Market
10.21.4 Financials
10.21.4.1 Financial Summary
10.21.5 SWOT Analysis
11 REPORT SCOPE AND METHODOLOGY
11.1 Scope of the Report
11.2 Global NIPT Market Segmentation
11.3 Research Methodology
11.3.1 Primary Research
11.3.2 Secondary Research
11.3.3 Key Data Points from Primary Sources
11.3.4 Key Data Points from Secondary Sources
11.3.5 Data Triangulation
11.3.6 Top-Down Approach (Segment Wise Analysis)
11.3.7 Bottom-Up Approach (Segmental Analysis)
11.4 Assumptions and Limitations
11.5 Data and Prediction Modelling
I Annexure 1: Recent Key Developments (2014 – 2018)
II Annexure 2: Product Mapping
III Annexure 3: Patent Landscape
1 MARKET OVERVIEW
1.1 Introduction
1.2 NIPT Approach
1.3 Different Methods of NIPT
1.4 Benefits and Risks Associated with NIPT
1.5 Technological Advancements
1.6 World Economic Outlook of Prenatal Testing Market, 2017
1.7 Global NIPT Market Scenario
1.8 Assumptions and Limitations for Market Size Calculations
2 MARKET DYNAMICS
2.1 Overview
2.2 Impact Analysis
2.3 Market Drivers
2.4 Market Restraints
2.5 Market Opportunities
3 COMPETITIVE LANDSCAPE
3.1 Introduction
3.2 Key Developments and Strategies
3.2.1 Product Launches and Enhancements
3.2.2 Joint Ventures, Partnerships, and Collaborations
3.2.3 Mergers and Acquisitions
3.2.4 Business Expansions, Awards, Recognitions, Certifications, and Others
3.3 Market Share Analysis
3.4 Growth Share Matrix (by Test), 2017
3.5 Growth Share Matrix (by Region), 2017
3.6 Key Stakeholders of NIPT Market
3.7 Industry Attractiveness
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Threat of New Entrants
3.7.4 Threat of Substitute Products
3.7.5 Intensity of Competitive Rivalry
4 INDUSTRY INSIGHTS
4.1 Introduction
4.2 Patent Analysis
4.3 Clinical Laboratory Improvement Amendments (CLIA) Program
4.4 List of Regulatory Bodies
5 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY TEST)
5.1 Overview
5.2 Verifi
5.3 MaterniT21 PLUS and MaterniT GENOME
5.4 PrenaTest, GeneSafe, and PrenatalSAFE
5.5 Panorama
5.6 QNatal Advanced
5.7 Harmony
5.8 IONA
5.9 NIFTY
5.10 Bambni
5.11 Others
6 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY METHOD)
6.1 Overview
6.2 cf-DNA
6.3 FCMB
7 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY PLATFORM)
7.1 Overview
7.2 NGS
7.3 MPSS
7.4 Others
8 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY APPLICATION)
8.1 Overview
8.2 Trisomy Detection
8.3 Microdeletion Detection
8.4 Others
9 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY REGION)
9.1 Overview
9.2 Global Insights
9.3 North America
9.3.1 North America Market Dynamics
9.3.2 North America Market (by Country)
9.3.2.1 The U.S.
9.3.2.2 Canada
9.4 Europe
9.4.1 Europe Market Dynamics
9.4.2 Europe Market (by Country)
9.4.2.1 The U.K.
9.4.2.2 Germany
9.4.2.3 France
9.4.2.4 Italy
9.4.2.5 Spain
9.4.2.6 The Netherlands
9.4.2.7 Belgium
9.4.2.8 Switzerland
9.4.2.9 Sweden
9.4.2.10 Denmark
9.4.2.11 Poland
9.4.2.12 Russia
9.4.2.13 Rest-of-Europe
9.5 Asia-Pacific
9.5.1 Asia-Pacific Market Dynamics
9.5.2 Asia-Pacific (by Country)
9.5.2.1 China
9.5.2.2 Japan
9.5.2.3 Australia
9.5.2.4 India
9.5.2.5 Singapore
9.5.2.6 Hong Kong
9.5.2.7 Malaysia
9.5.2.8 Indonesia
9.5.2.9 Vietnam
9.5.2.10 South Korea
9.5.2.11 Philippines
9.5.2.12 Thailand
9.5.2.13 Rest-of-Asia-Pacific
9.6 Rest-of-the-World
10 COMPANY PROFILES
10.1 Overview
10.2 Agilent Technologies, Inc.
10.2.1 Overview
10.2.2 Corporate Summary
10.2.3 Product Offerings for Global NIPT Market
10.2.4 Financials
10.2.4.1 Financial Summary
10.2.5 SWOT Analysis
10.3 Annoroad Gene Technology
10.3.1 Overview
10.3.2 Corporate Summary
10.3.3 Product Offerings for Global NIPT Market
10.3.4 SWOT Analysis
10.4 Berry Genomics Co., Ltd.
10.4.1 Overview
10.4.2 Corporate Summary
10.4.3 Product Offerings for Global NIPT Market
10.4.4 SWOT Analysis
10.5 BGI Diagnosis
10.5.1 Overview
10.5.2 Corporate Summary
10.5.3 Product Offerings for Global NIPT Market
10.5.4 SWOT Analysis
10.6 Centogene AG
10.6.1 Overview
10.6.2 Corporate Summary
10.6.3 Product Offerings for Global NIPT Market
10.6.4 SWOT Analysis
10.7 Counsyl, Inc. (Subsidiary of Myriad Genetics, Inc.)
10.7.1 Overview
10.8 Myriad Genetics, Inc.
10.8.1 Overview
10.8.2 Corporate Summary
10.8.3 Product Offerings for Global NIPT Market
10.8.4 Financials
10.8.4.1 Financial Summary
10.8.5 SWOT Analysis
10.9 LifeCodexx AG (Subsidiary of Eurofins Scientific)
10.9.1 Overview
10.10 EUROFINS Genoma Group (Subsidiary of Eurofins Scientific)
10.10.1 Overview
10.11 Eurofins Scientific
10.11.1 Overview
10.11.2 Corporate Summary
10.11.3 Product Offerings for Global NIPT Market
10.11.4 Financials
10.11.4.1 Financial Summary
10.11.5 SWOT Analysis
10.12 F. Hoffmann-La Roche AG
10.12.1 Overview
10.12.2 Corporate Summary
10.12.3 Product Offerings for Global NIPT Market
10.12.4 Financials
10.12.4.1 Financial Summary
10.12.5 SWOT Analysis
10.13 Illumina, Inc.
10.13.1 Overview
10.13.2 Corporate Summary
10.13.3 Product Offerings for Global NIPT Market
10.13.4 Financials
10.13.4.1 Financial Summary
10.13.5 SWOT Analysis
10.14 Natera, Inc.
10.14.1 Overview
10.14.2 Corporate Summary
10.14.3 Product Offerings for Global NIPT Market
10.14.4 Financials
10.14.4.1 Financial Summary
10.14.5 SWOT Analysis
10.15 Next Biosciences
10.15.1 Overview
10.15.2 Corporate Summary
10.15.3 Product Offerings for Global NIPT Market
10.15.4 SWOT Analysis
10.16 NIPD Genetics
10.16.1 Overview
10.16.2 Corporate Summary
10.16.3 Product Offerings for Global NIPT Market
10.16.4 SWOT Analysis
10.17 PerkinElmer, Inc.
10.17.1 Overview
10.17.2 Corporate Summary
10.17.3 Product Offerings for Global NIPT Market
10.17.4 Financials
10.17.4.1 Financial Summary
10.17.5 SWOT Analysis
10.18 Premaitha Health Plc
10.18.1 Overview
10.18.2 Corporate Summary
10.18.3 Product Offerings for Global NIPT Market
10.18.4 Financials
10.18.4.1 Financial Summary
10.18.5 SWOT Analysis
10.19 Quest Diagnostics Incorporated
10.19.1 Overview
10.19.2 Corporate Summary
10.19.3 Product Offerings for Global NIPT Market
10.19.4 Financials
10.19.4.1 Financial Summary
10.19.5 SWOT Analysis
10.20 Sequenom, Inc. (Subsidiary of Laboratory Corporation of America Holdings)
10.20.1 Overview
10.21 Laboratory Corporation of America Holdings
10.21.1 Overview
10.21.2 Corporate Summary
10.21.3 Product Offerings for Global NIPT Market
10.21.4 Financials
10.21.4.1 Financial Summary
10.21.5 SWOT Analysis
11 REPORT SCOPE AND METHODOLOGY
11.1 Scope of the Report
11.2 Global NIPT Market Segmentation
11.3 Research Methodology
11.3.1 Primary Research
11.3.2 Secondary Research
11.3.3 Key Data Points from Primary Sources
11.3.4 Key Data Points from Secondary Sources
11.3.5 Data Triangulation
11.3.6 Top-Down Approach (Segment Wise Analysis)
11.3.7 Bottom-Up Approach (Segmental Analysis)
11.4 Assumptions and Limitations
11.5 Data and Prediction Modelling
I Annexure 1: Recent Key Developments (2014 – 2018)
II Annexure 2: Product Mapping
III Annexure 3: Patent Landscape
LIST OF TABLES
1 GLOBAL NIPT MARKET (2017 AND 2028)
2 MAJOR CHROMOSOMAL ANEUPLOIDIES
3 INCIDENCE RATE OF MAJOR CHROMOSOMAL ANEUPLOIDIES
4 TECHNOLOGICAL APPROACH FOR NIPT
5 IMPACT ANALYSIS OF MARKET DYNAMICS
6 LIST OF REGULATORY AUTHORITIES INVOLVED IN CLIA PROGRAM
7 LIST OF REGULATORY BODIES
8 NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
9 NIPT MARKET (BY TEST), 2017-2028, (UNITS)
10 NORTH AMERICA NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
11 NORTH AMERICA NIPT MARKET (BY TEST), 2017-2028, (UNITS)
12 EUROPE NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
13 EUROPE NIPT MARKET (BY TEST), 2017-2028, (UNITS)
14 EUROPE NIPT MARKET (BY COUNTRY), 2017-2028, ($MILLION)
15 EUROPE NIPT MARKET (BY COUNTRY), 2017-2028, (UNITS)
16 ASIA-PACIFIC NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
17 ASIA-PACIFIC NIPT MARKET (BY TEST), 2017-2028, (UNITS)
18 ASIA-PACIFIC NIPT MARKET (BY COUNTRY), 2017-2028, ($MILLION)
19 ASIA-PACIFIC NIPT MARKET (BY COUNTRY), 2017-2028, (UNITS)
20 REST-OF-THE-WORLD NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
21 REST-OF-THE-WORLD NIPT MARKET (BY TEST), 2017-2028, (UNITS)
1 GLOBAL NIPT MARKET (2017 AND 2028)
2 MAJOR CHROMOSOMAL ANEUPLOIDIES
3 INCIDENCE RATE OF MAJOR CHROMOSOMAL ANEUPLOIDIES
4 TECHNOLOGICAL APPROACH FOR NIPT
5 IMPACT ANALYSIS OF MARKET DYNAMICS
6 LIST OF REGULATORY AUTHORITIES INVOLVED IN CLIA PROGRAM
7 LIST OF REGULATORY BODIES
8 NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
9 NIPT MARKET (BY TEST), 2017-2028, (UNITS)
10 NORTH AMERICA NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
11 NORTH AMERICA NIPT MARKET (BY TEST), 2017-2028, (UNITS)
12 EUROPE NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
13 EUROPE NIPT MARKET (BY TEST), 2017-2028, (UNITS)
14 EUROPE NIPT MARKET (BY COUNTRY), 2017-2028, ($MILLION)
15 EUROPE NIPT MARKET (BY COUNTRY), 2017-2028, (UNITS)
16 ASIA-PACIFIC NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
17 ASIA-PACIFIC NIPT MARKET (BY TEST), 2017-2028, (UNITS)
18 ASIA-PACIFIC NIPT MARKET (BY COUNTRY), 2017-2028, ($MILLION)
19 ASIA-PACIFIC NIPT MARKET (BY COUNTRY), 2017-2028, (UNITS)
20 REST-OF-THE-WORLD NIPT MARKET (BY TEST), 2017-2028, ($MILLION)
21 REST-OF-THE-WORLD NIPT MARKET (BY TEST), 2017-2028, (UNITS)
LIST OF FIGURES
1 IMPACT OF MARKET DRIVERS AND MARKET RESTRAINTS
2 MARKET STATISTICS
3 GLOBAL NIPT MARKET (BY TEST), $MILLION
4 GLOBAL NIPT MARKET (BY TEST), UNITS
5 GLOBAL NIPT MARKET (BY METHOD), 2017
6 GLOBAL NIPT MARKET (BY METHOD), 2028
7 GLOBAL NIPT MARKET (BY APPLICATION), 2017
8 GLOBAL NIPT MARKET (BY APPLICATION), 2028
9 GLOBAL NIPT MARKET VALUE (BY REGION), 2017 AND 2028
10 GLOBAL NIPT MARKET VOLUME (BY REGION), 2017 AND 2028
11 GLOBAL NIPT MARKET (BY REGION), 2017
12 GLOBAL NIPT MARKET (BY REGION), 2028
13 PRENATAL TESTING TIMELINE DURING PREGNANCY
14 DIFFERENT INDICATIONS FOR NIPT
15 NIPT APPROACH
16 BENEFITS AND RISKS ASSOCIATED WITH NIPT
17 ECOSYSTEM PLAYERS OF GLOBAL PRENATAL TESTING MARKET
18 GLOBAL PRENATAL TESTING MARKET: OPPORTUNITY MATRIX
19 GLOBAL NIPT MARKET VALUE (2017-2028)
20 GLOBAL NIPT MARKET VOLUME (2017-2028)
21 COMPETITIVE LANDSCAPE (JANUARY 2014-AUGUST 2018)
22 SHARE OF KEY DEVELOPMENTS AND STRATEGIES (JANUARY 2014-AUGUST 2018)
23 PRODUCT LAUNCH SHARE, BY COMPANIES
24 JOINT VENTURES, PARTNERSHIPS, AND COLLABORATIONS SHARE, BY COMPANIES
25 MARKET SHARE ANALYSIS
26 GROWTH SHARE MATRIX (BY TEST), 2017
27 GROWTH SHARE MATRIX (BY REGION), 2017
28 PORTER’S FIVE FORCES ANALYSIS
29 INDUSTRY INSIGHTS (JANUARY 2014-AUGUST 2018)
30 PATENT SHARE (BY ASSIGNEE)
31 CLASSIFICATION OF TESTS IN CLIA PROGRAM
32 NIPT MARKET, BY TEST
33 GLOBAL NIPT MARKET (BY VERIFI), BY REVENUE, 2017-2028
34 GLOBAL NIPT MARKET (BY VERIFI), BY VOLUME, 2017-2028
35 GLOBAL NIPT MARKET (BY MATERNIT21 PLUS AND MATERNIT GENOME), BY REVENUE, 2017-2028
36 GLOBAL NIPT MARKET (BY MATERNIT21 PLUS AND MATERNIT GENOME), BY VOLUME, 2017-2028
37 GLOBAL NIPT MARKET (BY PRENATEST, GENESAFE, AND PRENATALSAFE), BY REVENUE, 2017-2028
38 GLOBAL NIPT MARKET (BY PRENATEST, GENESAFE, AND PRENATALSAFE), BY VOLUME, 2017-2028
39 GLOBAL NIPT MARKET (BY PANORAMA), BY REVENUE, 2017-2028
40 GLOBAL NIPT MARKET (BY PANORAMA), BY VOLUME, 2017-2028
41 GLOBAL NIPT MARKET (BY QNATAL ADVANCED), BY REVENUE, 2017-2028
42 GLOBAL NIPT MARKET (BY QNATAL ADVANCED), BY VOLUME, 2017-2028
43 GLOBAL NIPT MARKET (BY HARMONY), BY REVENUE, 2017-2028
44 GLOBAL NIPT MARKET (BY HARMONY), BY VOLUME, 2017-2028
45 GLOBAL NIPT MARKET (BY IONA), BY REVENUE, 2017-2028
46 GLOBAL NIPT MARKET (BY IONA), BY VOLUME, 2017-2028
47 GLOBAL NIPT MARKET (BY NIFTY), BY REVENUE, 2017-2028
48 GLOBAL NIPT MARKET (BY NIFTY), BY VOLUME, 2017-2028
49 GLOBAL NIPT MARKET (BY BAMBNI), BY REVENUE, 2017-2028
50 GLOBAL NIPT MARKET (BY BAMBNI), BY VOLUME, 2017-2028
51 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028
52 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028
53 GLOBAL NIPT MARKET SHARE (BY METHOD), 2017
54 GLOBAL NIPT MARKET (BY METHOD), BY REVENUE, 2017-2028
55 GLOBAL NIPT MARKET (BY METHOD), BY VOLUME, 2017-2028
56 GLOBAL NIPT MARKET (BY CF-DNA), BY REVENUE, 2017-2028
57 GLOBAL NIPT MARKET (BY CF-DNA), BY VOLUME, 2017-2028
58 GLOBAL NIPT MARKET (BY FCMB), BY REVENUE, 2017-2028
59 GLOBAL NIPT MARKET (BY FCMB), BY VOLUME, 2017-2028
60 GLOBAL NIPT MARKET SHARE (BY PLATFORM), 2017
61 GLOBAL NIPT MARKET (BY PLATFORM), BY REVENUE, 2017-2028
62 GLOBAL NIPT MARKET (BY PLATFORM), BY VOLUME, 2017-2028
63 GLOBAL NIPT MARKET (BY NGS), BY REVENUE, 2017-2028
64 GLOBAL NIPT MARKET (BY NGS), BY VOLUME, 2017-2028
65 GLOBAL NIPT MARKET (BY MPSS), BY REVENUE, 2017-2028
66 GLOBAL NIPT MARKET (BY MPSS), BY VOLUME, 2017-2028
67 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028
68 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028
69 GLOBAL NIPT MARKET SHARE (BY APPLICATION), 2017
70 GLOBAL NIPT MARKET (BY APPLICATION), BY REVENUE, 2017-2028
71 GLOBAL NIPT MARKET (BY APPLICATION), BY VOLUME, 2017-2028
72 GLOBAL NIPT MARKET (BY TRISOMY DETECTION), BY REVENUE, 2017-2028
73 GLOBAL NIPT MARKET (BY TRISOMY DETECTION), BY VOLUME, 2017-2028
74 GLOBAL NIPT MARKET (BY MICRODELETION DETECTION), BY REVENUE, 2017-2028
75 GLOBAL NIPT MARKET (BY MICRODELETION DETECTION), BY VOLUME, 2017-2028
76 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028
77 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028
78 GLOBAL NIPT MARKET (BY REGION), BY REVENUE, 2017-2028
79 GLOBAL NIPT MARKET (BY REGION), BY VOLUME, 2017-2028
80 GLOBAL NIPT MARKET SHARE, BY REGION (2017)
81 GLOBAL NIPT MARKET SHARE, BY REGION (2028)
82 NORTH AMERICA NIPT MARKET, BY REVENUE, 2017-2028
83 NORTH AMERICA NIPT MARKET, BY VOLUME, 2017-2028
84 NORTH AMERICA NIPT MARKET (BY COUNTRY), BY REVENUE, 2017-2028
85 NORTH AMERICA NIPT MARKET (BY COUNTRY), BY VOLUME, 2017-2028
86 THE U.S. NIPT MARKET, BY REVENUE, 2017-2028
87 THE U.S. NIPT MARKET, BY VOLUME, 2017-2028
88 CANADA NIPT MARKET, BY REVENUE, 2017-2028
89 CANADA NIPT MARKET, BY VOLUME, 2017-2028
90 EUROPE NIPT MARKET, BY REVENUE, 2017-2028
91 EUROPE NIPT MARKET, BY VOLUME, 2017-2028
92 THE U.K. NIPT MARKET, BY REVENUE, 2017-2028
93 THE U.K. NIPT MARKET, BY VOLUME, 2017-2028
94 GERMANY NIPT MARKET, BY REVENUE, 2017-2028
95 GERMANY NIPT MARKET, BY VOLUME, 2017-2028
96 FRANCE NIPT MARKET, BY REVENUE, 2017-2028
97 FRANCE NIPT MARKET, BY VOLUME, 2017-2028
98 ITALY NIPT MARKET, BY REVENUE, 2017-2028
99 ITALY NIPT MARKET, BY VOLUME, 2017-2028
100 SPAIN NIPT MARKET, BY REVENUE, 2017-2028
101 SPAIN NIPT MARKET, BY VOLUME, 2017-2028
102 THE NETHERLANDS NIPT MARKET, BY REVENUE, 2017-2028
103 THE NETHERLANDS NIPT MARKET, BY VOLUME, 2017-2028
104 BELGIUM NIPT MARKET, BY REVENUE, 2017-2028
105 BELGIUM NIPT MARKET, BY VOLUME, 2017-2028
106 SWITZERLAND NIPT MARKET, BY REVENUE, 2017-2028
107 SWITZERLAND NIPT MARKET, BY VOLUME, 2017-2028
108 SWEDEN NIPT MARKET, BY REVENUE, 2017-2028
109 SWEDEN NIPT MARKET, BY VOLUME, 2017-2028
110 DENMARK NIPT MARKET, BY REVENUE, 2017-2028
111 DENMARK NIPT MARKET, BY VOLUME, 2017-2028
112 POLAND NIPT MARKET, BY REVENUE, 2017-2028
113 POLAND NIPT MARKET, BY VOLUME, 2017-2028
114 RUSSIA NIPT MARKET, BY REVENUE, 2017-2028
115 RUSSIA NIPT MARKET, BY VOLUME, 2017-2028
116 REST-OF-EUROPE NIPT MARKET, BY REVENUE, 2017-2028
117 REST-OF-EUROPE NIPT MARKET, BY VOLUME, 2017-2028
118 ASIA-PACIFIC NIPT MARKET, BY REVENUE, 2017-2028
119 ASIA-PACIFIC NIPT MARKET, BY VOLUME, 2017-2028
120 CHINA NIPT MARKET, BY REVENUE, 2017-2028
121 CHINA NIPT MARKET, BY VOLUME, 2017-2028
122 JAPAN NIPT MARKET, BY REVENUE, 2017-2028
123 JAPAN NIPT MARKET, BY VOLUME, 2017-2028
124 AUSTRALIA NIPT MARKET, BY REVENUE, 2017-2028
125 AUSTRALIA NIPT MARKET, BY VOLUME, 2017-2028
126 INDIA NIPT MARKET, BY REVENUE, 2017-2028
127 INDIA NIPT MARKET, BY VOLUME, 2017-2028
128 SINGAPORE NIPT MARKET, BY REVENUE, 2017-2028
129 SINGAPORE NIPT MARKET, BY VOLUME, 2017-2028
130 HONG KONG NIPT MARKET, BY REVENUE, 2017-2028
131 HONG KONG NIPT MARKET, BY VOLUME, 2017-2028
132 MALAYSIA NIPT MARKET, BY REVENUE, 2017-2028
133 MALAYSIA NIPT MARKET, BY VOLUME, 2017-2028
134 INDONESIA NIPT MARKET, BY REVENUE, 2017-2028
135 INDONESIA NIPT MARKET, BY VOLUME, 2017-2028
136 VIETNAM NIPT MARKET, BY REVENUE, 2017-2028
137 VIETNAM NIPT MARKET, BY VOLUME, 2017-2028
138 SOUTH KOREA NIPT MARKET, BY REVENUE, 2017-2028
139 SOUTH KOREA NIPT MARKET, BY VOLUME, 2017-2028
140 PHILIPPINES NIPT MARKET, BY REVENUE, 2017-2028
141 PHILIPPINES NIPT MARKET, BY VOLUME, 2017-2028
142 THAILAND NIPT MARKET, BY REVENUE, 2017-2028
143 THAILAND NIPT MARKET, BY VOLUME, 2017-2028
144 REST-OF-ASIA-PACIFIC NIPT MARKET, BY REVENUE, 2017-2028
145 REST-OF-ASIA-PACIFIC NIPT MARKET, BY VOLUME, 2017-2028
146 REST-OF-THE-WORLD NIPT MARKET, BY REVENUE, 2017-2028
147 REST-OF-THE-WORLD NIPT MARKET, BY VOLUME, 2017-2028
148 SHARE OF KEY COMPANY PROFILES (BY COMPANY TYPE)
149 AGILENT TECHNOLOGIES, INC.: OVERALL PRODUCT PORTFOLIO
150 AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
151 AGILENT TECHNOLOGIES, INC.: OVERALL FINANCIALS (2015-2017)
152 AGILENT TECHNOLOGIES, INC.: REVENUE BY BUSINESS SEGMENTS (2015-2017)
153 AGILENT TECHNOLOGIES, INC.: REVENUE BY REGION (2015-2017)
154 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS
155 ANNOROAD GENE TECHNOLOGY: OVERALL PRODUCT PORTFOLIO
156 ANNOROAD GENE TECHNOLOGY: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
157 ANNOROAD GENE TECHNOLOGY: SWOT ANALYSIS
158 BERRY GENOMICS CO., LTD.: OVERALL PRODUCT PORTFOLIO
159 BERRY GENOMICS CO., LTD.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
160 BERRY GENOMICS CO., LTD.: SWOT ANALYSIS
161 BGI DIAGNOSIS: OVERALL PRODUCT PORTFOLIO
162 BGI DIAGNOSIS: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
163 BGI DIAGNOSIS: SWOT ANALYSIS
164 CENTOGENE AG: OVERALL PRODUCT PORTFOLIO
165 CENTOGENE AG: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
166 CENTOGENE AG: SWOT ANALYSIS
167 MYRIAD GENETICS, INC.: OVERALL PRODUCT PORTFOLIO
168 MYRIAD GENETICS, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
169 MYRIAD GENETICS, INC.: OVERALL FINANCIALS (2015-2017)
170 MYRIAD GENETICS, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
171 MYRIAD GENETICS, INC.: SWOT ANALYSIS
172 EUROFINS SCIENTIFIC: OVERALL PRODUCT PORTFOLIO
173 EUROFINS SCIENTIFIC: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
174 EUROFINS SCIENTIFIC: OVERALL FINANCIALS (2015-2017)
175 EUROFINS SCIENTIFIC: NET REVENUE BY REGION (2015-2017)
176 EUROFINS SCIENTIFIC: SWOT ANALYSIS
177 F. HOFFMANN-LA ROCHE AG: OVERALL PRODUCT PORTFOLIO
178 F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
179 F. HOFFMANN-LA ROCHE AG: OVERALL FINANCIALS (2015-2017)
180 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
181 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY DIAGNOSTICS SUB-DIVISION (2015-2017)
182 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY REGION (2015-2017)
183 F. HOFFMANN-LA ROCHE AG: SWOT ANALYSIS
184 ILLUMINA, INC.: OVERALL PRODUCT PORTFOLIO
185 ILLUMINA, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
186 ILLUMINA, INC.: OVERALL FINANCIALS (2015-2017)
187 ILLUMINA, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
188 ILLUMINA, INC.: NET REVENUE BY REGION (2015-2017)
189 ILLUMINA, INC.: SWOT ANALYSIS
190 NATERA, INC.: OVERALL PRODUCT PORTFOLIO
191 NATERA, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
192 NATERA, INC.: OVERALL FINANCIALS (2015-2017)
193 NATERA, INC.: REVENUE BY REGION (2015-2017)
194 NATERA, INC.: SWOT ANALYSIS
195 NEXT BIOSCIENCES: OVERALL PRODUCT PORTFOLIO
196 NEXT BIOSCIENCES: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
197 NEXT BIOSCIENCES: SWOT ANALYSIS
198 NIPD GENETICS: OVERALL PRODUCT PORTFOLIO
199 NIPD GENETICS: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
200 NIPD GENETICS : SWOT ANALYSIS
201 PERKINELMER, INC.: OVERALL PRODUCT PORTFOLIO
202 PERKINELMER, INC.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
203 PERKINELMER, INC.: OVERALL FINANCIALS (2015-2017)
204 PERKINELMER, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
205 PERKINELMER, INC.: NET REVENUE BY REGION (2015-2017)
206 PERKINELMER, INC.: SWOT ANALYSIS
207 PREMAITHA HEALTH PLC: OVERALL PRODUCT PORTFOLIO
208 PREMAITHA HEALTH PLC: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
209 PREMAITHA HEALTH: OVERALL FINANCIALS (2015-2017)
210 PREMAITHA HEALTH: NET REVENUE BY REGION (2015-2017)
211 PREMAITHA HEALTH PLC: SWOT ANALYSIS
212 QUEST DIAGNOSTICS INCORPORATED: OVERALL PRODUCT PORTFOLIO
213 QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
214 QUEST DIAGNOSTICS INCORPORATED: OVERALL FINANCIALS (2015-2017)
215 QUEST DIAGNOSTICS INCORPORATED: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
216 QUEST DIAGNOSTICS INCORPORATED: NET REVENUE BY DIS SEGMENT (2015-2017)
217 QUEST DIAGNOSTICS INCORPORATED: SWOT ANALYSIS
218 LABORATORY CORPORATION OF AMERICA HOLDINGS : OVERALL PRODUCT PORTFOLIO
219 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
220 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERALL FINANCIALS (2015-2017)
221 LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
222 LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE BY REGION (2015-2017)
223 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS
224 GLOBAL NIPT MARKET SEGMENTATION
225 CONSIDERED FACTORS FOR DATA PREDICTION AND MODELING
1 IMPACT OF MARKET DRIVERS AND MARKET RESTRAINTS
2 MARKET STATISTICS
3 GLOBAL NIPT MARKET (BY TEST), $MILLION
4 GLOBAL NIPT MARKET (BY TEST), UNITS
5 GLOBAL NIPT MARKET (BY METHOD), 2017
6 GLOBAL NIPT MARKET (BY METHOD), 2028
7 GLOBAL NIPT MARKET (BY APPLICATION), 2017
8 GLOBAL NIPT MARKET (BY APPLICATION), 2028
9 GLOBAL NIPT MARKET VALUE (BY REGION), 2017 AND 2028
10 GLOBAL NIPT MARKET VOLUME (BY REGION), 2017 AND 2028
11 GLOBAL NIPT MARKET (BY REGION), 2017
12 GLOBAL NIPT MARKET (BY REGION), 2028
13 PRENATAL TESTING TIMELINE DURING PREGNANCY
14 DIFFERENT INDICATIONS FOR NIPT
15 NIPT APPROACH
16 BENEFITS AND RISKS ASSOCIATED WITH NIPT
17 ECOSYSTEM PLAYERS OF GLOBAL PRENATAL TESTING MARKET
18 GLOBAL PRENATAL TESTING MARKET: OPPORTUNITY MATRIX
19 GLOBAL NIPT MARKET VALUE (2017-2028)
20 GLOBAL NIPT MARKET VOLUME (2017-2028)
21 COMPETITIVE LANDSCAPE (JANUARY 2014-AUGUST 2018)
22 SHARE OF KEY DEVELOPMENTS AND STRATEGIES (JANUARY 2014-AUGUST 2018)
23 PRODUCT LAUNCH SHARE, BY COMPANIES
24 JOINT VENTURES, PARTNERSHIPS, AND COLLABORATIONS SHARE, BY COMPANIES
25 MARKET SHARE ANALYSIS
26 GROWTH SHARE MATRIX (BY TEST), 2017
27 GROWTH SHARE MATRIX (BY REGION), 2017
28 PORTER’S FIVE FORCES ANALYSIS
29 INDUSTRY INSIGHTS (JANUARY 2014-AUGUST 2018)
30 PATENT SHARE (BY ASSIGNEE)
31 CLASSIFICATION OF TESTS IN CLIA PROGRAM
32 NIPT MARKET, BY TEST
33 GLOBAL NIPT MARKET (BY VERIFI), BY REVENUE, 2017-2028
34 GLOBAL NIPT MARKET (BY VERIFI), BY VOLUME, 2017-2028
35 GLOBAL NIPT MARKET (BY MATERNIT21 PLUS AND MATERNIT GENOME), BY REVENUE, 2017-2028
36 GLOBAL NIPT MARKET (BY MATERNIT21 PLUS AND MATERNIT GENOME), BY VOLUME, 2017-2028
37 GLOBAL NIPT MARKET (BY PRENATEST, GENESAFE, AND PRENATALSAFE), BY REVENUE, 2017-2028
38 GLOBAL NIPT MARKET (BY PRENATEST, GENESAFE, AND PRENATALSAFE), BY VOLUME, 2017-2028
39 GLOBAL NIPT MARKET (BY PANORAMA), BY REVENUE, 2017-2028
40 GLOBAL NIPT MARKET (BY PANORAMA), BY VOLUME, 2017-2028
41 GLOBAL NIPT MARKET (BY QNATAL ADVANCED), BY REVENUE, 2017-2028
42 GLOBAL NIPT MARKET (BY QNATAL ADVANCED), BY VOLUME, 2017-2028
43 GLOBAL NIPT MARKET (BY HARMONY), BY REVENUE, 2017-2028
44 GLOBAL NIPT MARKET (BY HARMONY), BY VOLUME, 2017-2028
45 GLOBAL NIPT MARKET (BY IONA), BY REVENUE, 2017-2028
46 GLOBAL NIPT MARKET (BY IONA), BY VOLUME, 2017-2028
47 GLOBAL NIPT MARKET (BY NIFTY), BY REVENUE, 2017-2028
48 GLOBAL NIPT MARKET (BY NIFTY), BY VOLUME, 2017-2028
49 GLOBAL NIPT MARKET (BY BAMBNI), BY REVENUE, 2017-2028
50 GLOBAL NIPT MARKET (BY BAMBNI), BY VOLUME, 2017-2028
51 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028
52 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028
53 GLOBAL NIPT MARKET SHARE (BY METHOD), 2017
54 GLOBAL NIPT MARKET (BY METHOD), BY REVENUE, 2017-2028
55 GLOBAL NIPT MARKET (BY METHOD), BY VOLUME, 2017-2028
56 GLOBAL NIPT MARKET (BY CF-DNA), BY REVENUE, 2017-2028
57 GLOBAL NIPT MARKET (BY CF-DNA), BY VOLUME, 2017-2028
58 GLOBAL NIPT MARKET (BY FCMB), BY REVENUE, 2017-2028
59 GLOBAL NIPT MARKET (BY FCMB), BY VOLUME, 2017-2028
60 GLOBAL NIPT MARKET SHARE (BY PLATFORM), 2017
61 GLOBAL NIPT MARKET (BY PLATFORM), BY REVENUE, 2017-2028
62 GLOBAL NIPT MARKET (BY PLATFORM), BY VOLUME, 2017-2028
63 GLOBAL NIPT MARKET (BY NGS), BY REVENUE, 2017-2028
64 GLOBAL NIPT MARKET (BY NGS), BY VOLUME, 2017-2028
65 GLOBAL NIPT MARKET (BY MPSS), BY REVENUE, 2017-2028
66 GLOBAL NIPT MARKET (BY MPSS), BY VOLUME, 2017-2028
67 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028
68 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028
69 GLOBAL NIPT MARKET SHARE (BY APPLICATION), 2017
70 GLOBAL NIPT MARKET (BY APPLICATION), BY REVENUE, 2017-2028
71 GLOBAL NIPT MARKET (BY APPLICATION), BY VOLUME, 2017-2028
72 GLOBAL NIPT MARKET (BY TRISOMY DETECTION), BY REVENUE, 2017-2028
73 GLOBAL NIPT MARKET (BY TRISOMY DETECTION), BY VOLUME, 2017-2028
74 GLOBAL NIPT MARKET (BY MICRODELETION DETECTION), BY REVENUE, 2017-2028
75 GLOBAL NIPT MARKET (BY MICRODELETION DETECTION), BY VOLUME, 2017-2028
76 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028
77 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028
78 GLOBAL NIPT MARKET (BY REGION), BY REVENUE, 2017-2028
79 GLOBAL NIPT MARKET (BY REGION), BY VOLUME, 2017-2028
80 GLOBAL NIPT MARKET SHARE, BY REGION (2017)
81 GLOBAL NIPT MARKET SHARE, BY REGION (2028)
82 NORTH AMERICA NIPT MARKET, BY REVENUE, 2017-2028
83 NORTH AMERICA NIPT MARKET, BY VOLUME, 2017-2028
84 NORTH AMERICA NIPT MARKET (BY COUNTRY), BY REVENUE, 2017-2028
85 NORTH AMERICA NIPT MARKET (BY COUNTRY), BY VOLUME, 2017-2028
86 THE U.S. NIPT MARKET, BY REVENUE, 2017-2028
87 THE U.S. NIPT MARKET, BY VOLUME, 2017-2028
88 CANADA NIPT MARKET, BY REVENUE, 2017-2028
89 CANADA NIPT MARKET, BY VOLUME, 2017-2028
90 EUROPE NIPT MARKET, BY REVENUE, 2017-2028
91 EUROPE NIPT MARKET, BY VOLUME, 2017-2028
92 THE U.K. NIPT MARKET, BY REVENUE, 2017-2028
93 THE U.K. NIPT MARKET, BY VOLUME, 2017-2028
94 GERMANY NIPT MARKET, BY REVENUE, 2017-2028
95 GERMANY NIPT MARKET, BY VOLUME, 2017-2028
96 FRANCE NIPT MARKET, BY REVENUE, 2017-2028
97 FRANCE NIPT MARKET, BY VOLUME, 2017-2028
98 ITALY NIPT MARKET, BY REVENUE, 2017-2028
99 ITALY NIPT MARKET, BY VOLUME, 2017-2028
100 SPAIN NIPT MARKET, BY REVENUE, 2017-2028
101 SPAIN NIPT MARKET, BY VOLUME, 2017-2028
102 THE NETHERLANDS NIPT MARKET, BY REVENUE, 2017-2028
103 THE NETHERLANDS NIPT MARKET, BY VOLUME, 2017-2028
104 BELGIUM NIPT MARKET, BY REVENUE, 2017-2028
105 BELGIUM NIPT MARKET, BY VOLUME, 2017-2028
106 SWITZERLAND NIPT MARKET, BY REVENUE, 2017-2028
107 SWITZERLAND NIPT MARKET, BY VOLUME, 2017-2028
108 SWEDEN NIPT MARKET, BY REVENUE, 2017-2028
109 SWEDEN NIPT MARKET, BY VOLUME, 2017-2028
110 DENMARK NIPT MARKET, BY REVENUE, 2017-2028
111 DENMARK NIPT MARKET, BY VOLUME, 2017-2028
112 POLAND NIPT MARKET, BY REVENUE, 2017-2028
113 POLAND NIPT MARKET, BY VOLUME, 2017-2028
114 RUSSIA NIPT MARKET, BY REVENUE, 2017-2028
115 RUSSIA NIPT MARKET, BY VOLUME, 2017-2028
116 REST-OF-EUROPE NIPT MARKET, BY REVENUE, 2017-2028
117 REST-OF-EUROPE NIPT MARKET, BY VOLUME, 2017-2028
118 ASIA-PACIFIC NIPT MARKET, BY REVENUE, 2017-2028
119 ASIA-PACIFIC NIPT MARKET, BY VOLUME, 2017-2028
120 CHINA NIPT MARKET, BY REVENUE, 2017-2028
121 CHINA NIPT MARKET, BY VOLUME, 2017-2028
122 JAPAN NIPT MARKET, BY REVENUE, 2017-2028
123 JAPAN NIPT MARKET, BY VOLUME, 2017-2028
124 AUSTRALIA NIPT MARKET, BY REVENUE, 2017-2028
125 AUSTRALIA NIPT MARKET, BY VOLUME, 2017-2028
126 INDIA NIPT MARKET, BY REVENUE, 2017-2028
127 INDIA NIPT MARKET, BY VOLUME, 2017-2028
128 SINGAPORE NIPT MARKET, BY REVENUE, 2017-2028
129 SINGAPORE NIPT MARKET, BY VOLUME, 2017-2028
130 HONG KONG NIPT MARKET, BY REVENUE, 2017-2028
131 HONG KONG NIPT MARKET, BY VOLUME, 2017-2028
132 MALAYSIA NIPT MARKET, BY REVENUE, 2017-2028
133 MALAYSIA NIPT MARKET, BY VOLUME, 2017-2028
134 INDONESIA NIPT MARKET, BY REVENUE, 2017-2028
135 INDONESIA NIPT MARKET, BY VOLUME, 2017-2028
136 VIETNAM NIPT MARKET, BY REVENUE, 2017-2028
137 VIETNAM NIPT MARKET, BY VOLUME, 2017-2028
138 SOUTH KOREA NIPT MARKET, BY REVENUE, 2017-2028
139 SOUTH KOREA NIPT MARKET, BY VOLUME, 2017-2028
140 PHILIPPINES NIPT MARKET, BY REVENUE, 2017-2028
141 PHILIPPINES NIPT MARKET, BY VOLUME, 2017-2028
142 THAILAND NIPT MARKET, BY REVENUE, 2017-2028
143 THAILAND NIPT MARKET, BY VOLUME, 2017-2028
144 REST-OF-ASIA-PACIFIC NIPT MARKET, BY REVENUE, 2017-2028
145 REST-OF-ASIA-PACIFIC NIPT MARKET, BY VOLUME, 2017-2028
146 REST-OF-THE-WORLD NIPT MARKET, BY REVENUE, 2017-2028
147 REST-OF-THE-WORLD NIPT MARKET, BY VOLUME, 2017-2028
148 SHARE OF KEY COMPANY PROFILES (BY COMPANY TYPE)
149 AGILENT TECHNOLOGIES, INC.: OVERALL PRODUCT PORTFOLIO
150 AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
151 AGILENT TECHNOLOGIES, INC.: OVERALL FINANCIALS (2015-2017)
152 AGILENT TECHNOLOGIES, INC.: REVENUE BY BUSINESS SEGMENTS (2015-2017)
153 AGILENT TECHNOLOGIES, INC.: REVENUE BY REGION (2015-2017)
154 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS
155 ANNOROAD GENE TECHNOLOGY: OVERALL PRODUCT PORTFOLIO
156 ANNOROAD GENE TECHNOLOGY: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
157 ANNOROAD GENE TECHNOLOGY: SWOT ANALYSIS
158 BERRY GENOMICS CO., LTD.: OVERALL PRODUCT PORTFOLIO
159 BERRY GENOMICS CO., LTD.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
160 BERRY GENOMICS CO., LTD.: SWOT ANALYSIS
161 BGI DIAGNOSIS: OVERALL PRODUCT PORTFOLIO
162 BGI DIAGNOSIS: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
163 BGI DIAGNOSIS: SWOT ANALYSIS
164 CENTOGENE AG: OVERALL PRODUCT PORTFOLIO
165 CENTOGENE AG: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
166 CENTOGENE AG: SWOT ANALYSIS
167 MYRIAD GENETICS, INC.: OVERALL PRODUCT PORTFOLIO
168 MYRIAD GENETICS, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
169 MYRIAD GENETICS, INC.: OVERALL FINANCIALS (2015-2017)
170 MYRIAD GENETICS, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
171 MYRIAD GENETICS, INC.: SWOT ANALYSIS
172 EUROFINS SCIENTIFIC: OVERALL PRODUCT PORTFOLIO
173 EUROFINS SCIENTIFIC: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
174 EUROFINS SCIENTIFIC: OVERALL FINANCIALS (2015-2017)
175 EUROFINS SCIENTIFIC: NET REVENUE BY REGION (2015-2017)
176 EUROFINS SCIENTIFIC: SWOT ANALYSIS
177 F. HOFFMANN-LA ROCHE AG: OVERALL PRODUCT PORTFOLIO
178 F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
179 F. HOFFMANN-LA ROCHE AG: OVERALL FINANCIALS (2015-2017)
180 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
181 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY DIAGNOSTICS SUB-DIVISION (2015-2017)
182 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY REGION (2015-2017)
183 F. HOFFMANN-LA ROCHE AG: SWOT ANALYSIS
184 ILLUMINA, INC.: OVERALL PRODUCT PORTFOLIO
185 ILLUMINA, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
186 ILLUMINA, INC.: OVERALL FINANCIALS (2015-2017)
187 ILLUMINA, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
188 ILLUMINA, INC.: NET REVENUE BY REGION (2015-2017)
189 ILLUMINA, INC.: SWOT ANALYSIS
190 NATERA, INC.: OVERALL PRODUCT PORTFOLIO
191 NATERA, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
192 NATERA, INC.: OVERALL FINANCIALS (2015-2017)
193 NATERA, INC.: REVENUE BY REGION (2015-2017)
194 NATERA, INC.: SWOT ANALYSIS
195 NEXT BIOSCIENCES: OVERALL PRODUCT PORTFOLIO
196 NEXT BIOSCIENCES: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
197 NEXT BIOSCIENCES: SWOT ANALYSIS
198 NIPD GENETICS: OVERALL PRODUCT PORTFOLIO
199 NIPD GENETICS: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
200 NIPD GENETICS : SWOT ANALYSIS
201 PERKINELMER, INC.: OVERALL PRODUCT PORTFOLIO
202 PERKINELMER, INC.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
203 PERKINELMER, INC.: OVERALL FINANCIALS (2015-2017)
204 PERKINELMER, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
205 PERKINELMER, INC.: NET REVENUE BY REGION (2015-2017)
206 PERKINELMER, INC.: SWOT ANALYSIS
207 PREMAITHA HEALTH PLC: OVERALL PRODUCT PORTFOLIO
208 PREMAITHA HEALTH PLC: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
209 PREMAITHA HEALTH: OVERALL FINANCIALS (2015-2017)
210 PREMAITHA HEALTH: NET REVENUE BY REGION (2015-2017)
211 PREMAITHA HEALTH PLC: SWOT ANALYSIS
212 QUEST DIAGNOSTICS INCORPORATED: OVERALL PRODUCT PORTFOLIO
213 QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET
214 QUEST DIAGNOSTICS INCORPORATED: OVERALL FINANCIALS (2015-2017)
215 QUEST DIAGNOSTICS INCORPORATED: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
216 QUEST DIAGNOSTICS INCORPORATED: NET REVENUE BY DIS SEGMENT (2015-2017)
217 QUEST DIAGNOSTICS INCORPORATED: SWOT ANALYSIS
218 LABORATORY CORPORATION OF AMERICA HOLDINGS : OVERALL PRODUCT PORTFOLIO
219 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET
220 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERALL FINANCIALS (2015-2017)
221 LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE BY BUSINESS SEGMENT (2015-2017)
222 LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE BY REGION (2015-2017)
223 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS
224 GLOBAL NIPT MARKET SEGMENTATION
225 CONSIDERED FACTORS FOR DATA PREDICTION AND MODELING
